IL6 and breast cancer: The study of exosomal miR-9 and miR-181a highlights a key mechanism of MDSC expansion and T-cell immunosuppression driven by IL-6 in breast cancer and targetable pathways to combat breast cancer-mediated immunosuppression (277).